(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Hilary Duff releases 'Mature,' her 1st song in 10 years - 2RFK Jr. releases new dietary guidelines with emphasis on protein, full-fat dairy
- 3European Travel Objections for 2024
- 4Figure out How to Modify Your Pre-assembled Home for Greatest Solace and Stylish Allure
- 5In these U.S. groups, deaths now exceed births. What’s happening?
- The Best Computer games for Multiplayer Fun
- Change Your Physical make-up: Compelling Activities for Muscle Building
- Extraordinary Guinness World Records That Will Astound You
- Figure out How to Get a good deal on Your Rooftop Substitution Venture
- Holocaust survivor, descendants urge High Court to allow Gaza children medical access
- Distributed storage Answers for Information Reinforcement
- NASA is sending astronauts back to the moon. Can you see the Artemis 4 landing sites from Earth?
- Parents who delay baby's first vaccines also likely to skip measles shots
- 'I was diagnosed with incurable brain cancer on holiday'
